- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Immunoassays.
Displaying page 1 of 1.
EudraCT Number: 2020-003154-80 | Sponsor Protocol Number: 2020CLI | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Mucos Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment with Bromelain, Trypsin and Rutoside versus Placebo in Subjects wi... | |||||||||||||
Medical condition: Subjects suffering from knee Osteoarthitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002475-26 | Sponsor Protocol Number: GD2CAR01 | Start Date*: 2017-12-22 | |||||||||||
Sponsor Name:IRCCS Ospedale Pediatrico Bambino Gesù | |||||||||||||
Full Title: Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma | |||||||||||||
Medical condition: High Risk and/or relapsed/refractory Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005483-25 | Sponsor Protocol Number: SMT19969/C003 | Start Date*: 2014-10-08 | |||||||||||
Sponsor Name:Summit (Oxford) Limited | |||||||||||||
Full Title: A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days f... | |||||||||||||
Medical condition: Clostridium difficile infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002088-16 | Sponsor Protocol Number: CD19-CAR01 | Start Date*: 2017-12-22 | |||||||||||
Sponsor Name:Bambino Gesù Children's Hospital | |||||||||||||
Full Title: Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001939-31 | Sponsor Protocol Number: 101-PR-PRI-196 | Start Date*: 2013-02-13 | |||||||||||
Sponsor Name:LABORATORIOS LETI S.L.U | |||||||||||||
Full Title: Biological standardization of Dermatophagoides pteronyssinus allergen extract to determine the biological activity in histamine equivalent units (HEP). | |||||||||||||
Medical condition: Allergy to Dermatophagoides pteronyssinus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000056-14 | Sponsor Protocol Number: 06/DTD/3791E | Start Date*: 2008-03-03 | ||||||||||||||||
Sponsor Name:Cardiff University | ||||||||||||||||||
Full Title: Determination of method-specific normal cortisol and adrenal hormone responses to the short Synacthen test | ||||||||||||||||||
Medical condition: Normal, healthy volunteers to establish a reference range for the synacthen test, plus patients with hypoadrenalism/hypopituitarism | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005063-16 | Sponsor Protocol Number: IEO370 | Start Date*: 2017-07-17 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: A randomized presurgical study with different schedules of exemestane in postmenopausal women with stage 0-II ER-positive breast cancer | |||||||||||||
Medical condition: Postmenopausal ER positive breast cancer, waiting for surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001238-16 | Sponsor Protocol Number: CNTO1959PSO3012 | Start Date*: 2019-01-03 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Type Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001861-14 | Sponsor Protocol Number: UMCUMMR | Start Date*: 2008-02-07 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: Multicenter randomized clinical trial in Patients with Juvenile Idiopathic Athritis: Safety and efficacy of vaccination with live attenuated Measles, Mumps, Rubella vaccine | |||||||||||||
Medical condition: Juvenile Idiopathic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003678-42 | Sponsor Protocol Number: IIV-316 | Start Date*: 2017-09-01 |
Sponsor Name:RIVM [...] | ||
Full Title: Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands... | ||
Medical condition: Pertussis infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) FI (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001494-91 | Sponsor Protocol Number: CCRG12-001 | Start Date*: 2012-10-11 | ||||||||||||||||
Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
Full Title: Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in adult patients with acute myeloid leukemia: a multicenter randomized phase II trial | ||||||||||||||||||
Medical condition: Adult patients with acute myeloid leukemia in complete remission | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004729-55 | Sponsor Protocol Number: GD2CAR02 | Start Date*: 2023-07-14 | |||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | |||||||||||||
Full Title: Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory central nervous system tumors | |||||||||||||
Medical condition: Relapsed/refractory malignant central nervous system tumors | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001691-41 | Sponsor Protocol Number: EMN29 | Start Date*: 2021-12-28 | |||||||||||
Sponsor Name:European Myeloma Network | |||||||||||||
Full Title: A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
